STOCK TITAN
  1. Home
  2. Sec-filings
  3. VCYT
  4. [Form 4] Veracyte, Inc. Insider Trading Activity

Veracyte (VCYT) CEO Executes 10b5-1 Sale of 7,667 Shares

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Marc Stapley, Chief Executive Officer and Director of Veracyte, Inc. (VCYT), sold 7,667 shares of the company's common stock on 09/04/2025 under a pre-established Rule 10b5-1 trading plan adopted on 09/13/2024. The transaction was reported at a weighted-average sale price of $30.4073, with individual sale prices ranging from $30.22 to $30.66. After the reported sale, the filing shows Mr. Stapley beneficially owns 334,185 shares. The Form 4 was executed by an attorney-in-fact and includes customary disclosure that detailed per-price share breakdowns are available upon request.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine insider sale under a 10b5-1 plan; not an immediate red flag but reduces CEO's reported stake.

The sale of 7,667 shares at a weighted-average price of $30.4073 was executed under a pre-existing 10b5-1 plan adopted on 09/13/2024, indicating the trades were pre-planned and not opportunistic. The remaining beneficial ownership of 334,185 shares remains substantial in absolute terms, though this single small-scale disposal modestly reduces insider holdings. No additional context on proportionate ownership or intent was provided in the filing.

TL;DR: Disclosure follows standard governance practice for pre-planned insider trades; documentation appears complete.

The Form 4 discloses the Rule 10b5-1 plan adoption date and provides weighted-average pricing with a price range. Execution by attorney-in-fact and availability of per-price details on request align with compliance norms. There are no indications of off-plan or suspicious transactions in this filing; material governance concerns are not evident from the disclosed data alone.

Insider Stapley Marc
Role Chief Executive Officer
Sold 7,667 shs ($233K)
Type Security Shares Price Value
Sale Common Stock 7,667 $30.4073 $233K
Holdings After Transaction: Common Stock — 334,185 shares (Direct)
Footnotes (1)
  1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 13, 2024. Represents weighted average sales price. Sale prices for the transactions range from $30.22 to $30.66. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stapley Marc
(Last) (First) (Middle)
6000 SHORELINE COURT
SUITE 300
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/04/2025 S(1) 7,667 D $30.4073(2) 334,185 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 13, 2024.
2. Represents weighted average sales price. Sale prices for the transactions range from $30.22 to $30.66. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Remarks:
/s/ Jonathan Wygant, as attorney-in-fact 09/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Veracyte CEO Marc Stapley sell on 09/04/2025 (VCYT)?

He sold 7,667 shares of Veracyte common stock on 09/04/2025 under a Rule 10b5-1 plan.

At what price were the VCYT shares sold by the CEO?

The filing reports a weighted-average sale price of $30.4073, with individual sale prices ranging from $30.22 to $30.66.

How many VCYT shares does Marc Stapley beneficially own after the sale?

Following the reported transaction, he beneficially owns 334,185 shares according to the Form 4.

Was the sale part of a pre-established trading plan for VCYT insider?

Yes. The transactions were made pursuant to a Rule 10b5-1 plan adopted on 09/13/2024.

Where can I find detailed per-price share sale breakdowns for this VCYT Form 4?

The Form 4 states that detailed information about the number of shares sold at each separate price is available to the SEC, the issuer, or a shareholder upon request.